Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Torsdag 31 Oktober | 13:18:08 Europe / Stockholm

Svenska | English

BioStock

SynAct Pharma's Chairman to BioStock: "We are confident we have the right strategy"

2024-10-02 08:15:00

SynAct Pharma's Capital Markets Day provided detailed information regarding the revised strategy for its lead asset, resomelagon. The company focuses on the phase IIb ADVANCE study in early, severe rheumatoid arthritis, which is now up and running in the US. In parallel, the company is engaging in partnering discussions to strike a deal for phase III studies and beyond.
- SynAct has a clear strategy, the right team and fresh funding to continue with its plan, says Anders Kronborg, Chairman of the Board.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/10/synact-pharmas-chairman-we-are-confident-we-have-the-right-strategy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden